Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone/formoterol BAI versus Relvar Ellipta in partially controlled or uncontrolled asthma
2015-000801-38Phase 3Completed
- Sponsor
- Mundipharma
- Start
- Jan 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in asthma comparing Fluticasone/formoterol BAI with Relvar Ellipta DPI (2 arms). Primary endpoint: Change in peripheral airway resistance (R5-R20). Started Jan 2016; status: completed.
02
Drugs
fluticasone propionate + formoterolfluticasone propionate + vilanterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2015-000801-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000801-38.